During the past years, solid allograft rejection has been considered the consequence of either cellular or antibody mediated reaction both being part of the adaptive immune response, while the role of innate immunity has been mostly considered less relevant. Recently, a large body of evidence suggested that the innate immune response and its soluble mediators may play a more important role during solid allograft rejection than originally thought. This review will highlight the role of novel soluble mediators that are involved in the activation of innate immunity during alloimmune response and solid allograft rejection. We will also discuss emerging strategies to alleviate the aforementioned events. Hence, novel, feasible and safe clinical therapies are needed in order to prevent allograft loss in solid organ transplantation. Fully understanding the role of soluble mediators of innate immune system activation may help to mitigate solid allograft rejection and improve transplanted recipients' outcomes.

Novel Soluble Mediators of Innate Immune System Activation in Solid Allograft Rejection / V. Usuelli, C. Loretelli, A.J. Seelam, I. Pastore, F. D'Addio, M. Ben Nasr, P. Fiorina. - In: TRANSPLANTATION. - ISSN 0041-1337. - (2021). [Epub ahead of print] [10.1097/TP.0000000000003834]

Novel Soluble Mediators of Innate Immune System Activation in Solid Allograft Rejection

V. Usuelli
Primo
;
C. Loretelli
Secondo
;
A.J. Seelam;I. Pastore;F. D'Addio;M. Ben Nasr
Penultimo
;
P. Fiorina
Ultimo
2021

Abstract

During the past years, solid allograft rejection has been considered the consequence of either cellular or antibody mediated reaction both being part of the adaptive immune response, while the role of innate immunity has been mostly considered less relevant. Recently, a large body of evidence suggested that the innate immune response and its soluble mediators may play a more important role during solid allograft rejection than originally thought. This review will highlight the role of novel soluble mediators that are involved in the activation of innate immunity during alloimmune response and solid allograft rejection. We will also discuss emerging strategies to alleviate the aforementioned events. Hence, novel, feasible and safe clinical therapies are needed in order to prevent allograft loss in solid organ transplantation. Fully understanding the role of soluble mediators of innate immune system activation may help to mitigate solid allograft rejection and improve transplanted recipients' outcomes.
Settore MED/13 - Endocrinologia
2021
25-mag-2021
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/847453
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact